Search
for
Sort by
Research 361–390 of 1000+
- The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Alopecia Areata after COVID-19 Vaccines
- Serum-Based Assessment of Alopecia Areata Response to Treatment Using ATR-FTIR Spectroscopy
- Adjuvant Scalp Rolling for Patients With Refractory Alopecia Areata
- Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- Stem cell-based therapies for alopecia areata: a narrative review
- Exosome-Based Therapies for Alopecia Areata: A Systematic Review of Clinical and Experimental Evidence
- T <sub>H</sub> 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
- Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Intranasal sensitization model of alopecia areata using pertussis toxin as adjuvant
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- The potential of regulatory T cell-based therapies for alopecia areata
- Entdeckung von Autoantigenen bei der Haarverluststörung Alopecia areata: Implikation von posttranslationalen Modifikationen
- Oxidative stress management in the hair follicle: Could targeting NRF2 counter age‐related hair disorders and beyond?
- Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches
- Burden of immune-related skin diseases worldwide, 1991–2021: insights and prediction from the Global Burden of Disease Study
- Alopecia Areata, Primary Sclerosing Cholangitis, and Ulcerative Colitis: Autoimmunity and Apoptosis as Common Links?
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Aberrant inflammasome activation as a driving force of human autoimmune skin disease
- Noval advance of histone modification in inflammatory skin diseases and related treatment methods
- Association between SQSTM1 dysregulation and risk in alopecia areata: a Mendelian randomization study
- The role of lymphocytes in the development and treatment of alopecia areata
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Reduced level of 25-hydroxyvitamin D in chronic/relapsing Alopecia Areata
- Stress-induced sympathetic hyperactivation drives hair follicle necrosis to trigger autoimmunity
- An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
- Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy